Expert Review of Respiratory Medicine最新文献_第9页

Sleep apnea is associated with the increase of certain genera of Ruminococcaceae and Lachnospiraceae in the gut microbiome of hypertensive patients. 睡眠呼吸暂停与高血压患者肠道微生物群中瘤胃球菌科和毛螺科某些属的增加有关。

IF 3.9 3区医学

Expert Review of Respiratory Medicine Pub Date : 2022-11-01 DOI: 10.1080/17476348.2022.2147509

Cheng Zhang, Fengwei Chen, Yane Shen, Yuqing Chen, Jing Ma

{"title":"Sleep apnea is associated with the increase of certain genera of Ruminococcaceae and Lachnospiraceae in the gut microbiome of hypertensive patients.","authors":"Cheng Zhang, Fengwei Chen, Yane Shen, Yuqing Chen, Jing Ma","doi":"10.1080/17476348.2022.2147509","DOIUrl":"https://doi.org/10.1080/17476348.2022.2147509","url":null,"abstract":"Background: Obstructive sleep apnea (OSA) and hypertension are interrelated diseases linked to gut dysbiosis. This study aimed to investigate the effect of OSA on the gut microbiome in the context of hypertension and vice versa.Research design and methods: Of 211 consecutively screened patients, 52 completed polysomnography study, medical history questionnaires, and fecal sample collection. 16S rRNA gene sequencing was performed on fecal samples, and diversity, richness, and microbial taxa were analyzed using bioinformatics.Results: Alpha diversity showed slightly decreased diversity in OSA and hypertension groups without significant difference, and the hypoxia burden index (HBI) showed a weak positive correlation with Chao1 index (r = 0.342, p < 0.05) in OSA patients. Firmicutes-to-Bacteroidetes ratio was higher in patients with than without OSA. In hypertensive patients, those with OSA had higher Ruminococcus_1, Lachnoclostridium, Lachnospira, [Ruminococcus]_torques_group, and unidentified Lachnospiraceae levels than those without OSA. Conversely, in OSA patients, hypertensive patients had lower Faecalibacterium and Lachnospiraceae_NK4A136_group levels.Conclusion: The present study suggests a possible compensatory mechanism for gut microbiome changes in sleep apnea pathophysiology. The positive correlation between HBI and alpha diversity, and increase in certain genera of Ruminococcaceae and Lachnospiraceae in OSA patients may represent an adaptive response to hypoxia.","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":"16 11-12","pages":"1247-1256"},"PeriodicalIF":3.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10608100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Health impact of e-cigarettes and heated tobacco products in chronic obstructive pulmonary disease: current and emerging evidence. 电子烟和加热烟草制品对慢性阻塞性肺病患者健康的影响：现有证据和新出现的证据。

IF 3.9 3区医学

Expert Review of Respiratory Medicine Pub Date : 2022-11-01 Epub Date: 2023-01-22 DOI: 10.1080/17476348.2023.2167716

Jaymin B Morjaria, Davide Campagna, Grazia Caci, Renee O'Leary, Riccardo Polosa

{"title":"Health impact of e-cigarettes and heated tobacco products in chronic obstructive pulmonary disease: current and emerging evidence.","authors":"Jaymin B Morjaria, Davide Campagna, Grazia Caci, Renee O'Leary, Riccardo Polosa","doi":"10.1080/17476348.2023.2167716","DOIUrl":"10.1080/17476348.2023.2167716","url":null,"abstract":"Introduction: Quitting is the only proven method to attenuate the progression of chronic obstructive pulmonary disease (COPD). However, most COPD smokers do not seem to respond to smoking cessation interventions and may benefit by lessening the negative health effects of long-term cigarette smoke exposure by switching to non-combustible nicotine delivery alternatives, such as heated tobacco products (HTPs) and e-cigarettes (ECs).Areas covered: Compared with conventional cigarettes, HTPs and ECs offer substantial reduction in exposure to toxic chemicals and have the potential to reduce harm from cigarette smoke when used as tobacco cigarette substitutes. In this review, we examine the available clinical studies and population surveys on the respiratory health effects of ECs and HTPs in COPD patients.Expert opinion: The current research on the impact of ECs and HTPs on COPD patients' health is limited, and more high-quality studies are needed to draw definitive conclusions. However, this review provides a comprehensive overview of the available literature for health professionals looking to advise COPD patients on the use of these products. While ECs and HTPs may offer some benefits in reducing harm from cigarette smoke, their long-term effects on COPD patients' health are still unclear.","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":"16 11-12","pages":"1213-1226"},"PeriodicalIF":3.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10613040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current pharmacogenomic recommendations in chronic respiratory diseases: Is there a biomarker ready for clinical implementation? 目前慢性呼吸系统疾病的药物基因组学建议:是否有可用于临床应用的生物标志物?

IF 3.9 3区医学

Expert Review of Respiratory Medicine Pub Date : 2022-11-01 DOI: 10.1080/17476348.2022.2149496

Ingrid Fricke-Galindo, Ramcés Falfán-Valencia

{"title":"Current pharmacogenomic recommendations in chronic respiratory diseases: Is there a biomarker ready for clinical implementation?","authors":"Ingrid Fricke-Galindo, Ramcés Falfán-Valencia","doi":"10.1080/17476348.2022.2149496","DOIUrl":"https://doi.org/10.1080/17476348.2022.2149496","url":null,"abstract":"Introduction: The study of genetic variants in response to different drugs has predominated in fields of medicine such as oncology and infectious diseases. In chronic respiratory diseases, the available pharmacogenomic information is scarce but not less relevant.Areas covered: We searched the pharmacogenomic recommendations for respiratory diseases in the Table of Pharmacogenomic Biomarkers in Drug Labeling (U.S. Food and Drug Administration), the Clinical Pharmacogenomics Implementation Consortium (CPIC), and PharmGKB. The main pharmacogenomics recommendation in this field is to assess CFTR variants for using ivacaftor and its combination. The drugs' labels for arformoterol, indacaterol, and umeclidinium indicate a lack of influence of genetic variants in the pharmacokinetics of these drugs. Further studies should evaluate the contribution of CYP2D6 and CYP2C19 variants for formoterol. In addition, there are reports of potential pharmacogenetic variants in the treatment with acetylcysteine (TOLLIP rs3750920) and captopril (ACE rs1799752). The genetic variations for warfarin also are presented in PharmGKB and CPIC for patients with pulmonary hypertension.Expert opinion: The pharmacogenomics recommendations for lung diseases are limited. The clinical implementation of pharmacogenomics in treating respiratory diseases will contribute to the quality of life of patients with chronic respiratory diseases.","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":"16 11-12","pages":"1145-1152"},"PeriodicalIF":3.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10608130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The bleeding risk and safety of repeated bronchoscopies with tissue sampling in patients with pulmonary lesions. 肺病变患者反复支气管镜及组织取样的出血风险和安全性。

IF 3.9 3区医学

Expert Review of Respiratory Medicine Pub Date : 2022-11-01 DOI: 10.1080/17476348.2022.2159382

Congcong Li, Yanyan Li, Faguang Jin, Liyan Bo

{"title":"The bleeding risk and safety of repeated bronchoscopies with tissue sampling in patients with pulmonary lesions.","authors":"Congcong Li, Yanyan Li, Faguang Jin, Liyan Bo","doi":"10.1080/17476348.2022.2159382","DOIUrl":"https://doi.org/10.1080/17476348.2022.2159382","url":null,"abstract":"Background: Many patients need repeated bronchoscopies with tissue sampling to obtain the final pathological results and guide the optimal subsequent treatment of pulmonary lesions. However, few studies have explored the safety of repeated biopsies.Methods: The records of patients who underwent bronchoscopy-guided tissue sampling because of pulmonary lesions at the respiratory department between 1 January 2008 and 31 December 2019 were revised. The patients' clinical characteristics, information about bronchoscopy and incidence of complications were collected and analyzed.Results: In total, 3899 bronchoscopy-guided tissue sampling procedures were conducted in the 1781 participants. There was no significant difference in the incidence of major complications between the initial bronchoscopies and repeated bronchoscopies (1.12% vs. 1.13%, χ2 < 0.01, df = 1, p = 0.98), as was the incidence of hemoptysis (χ2 = 2.18, df = 1, p = 0.14). However, the bleeding rate of patients who experienced bleeding during the first bronchoscopies was significantly higher than that of patients who did not experience bleeding (61.19% vs. 32.63%, χ2 = 253.00, df = 1, p < 0.01).Conclusions: For patients with pulmonary lesions, re-bronchoscopy with tissue sampling appears to infer the same risk of bleeding including severe bleeding as experienced during the initial bronchoscopy. However, it should be treated with discretion when performing repeated tissue sampling on patients who once bled.","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":"16 11-12","pages":"1257-1262"},"PeriodicalIF":3.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10609145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comprehensive clinical guide for Pneumocystis jirovecii pneumonia: a missing therapeutic target in HIV-uninfected patients. 一个全面的临床指南的肺囊虫肺炎:一个缺失的治疗目标，在hiv未感染的患者。

IF 3.9 3区医学

Expert Review of Respiratory Medicine Pub Date : 2022-11-01 DOI: 10.1080/17476348.2022.2152332

Ahmad R Alsayed, Abdullah Al-Dulaimi, Mohammad Alkhatib, Mohammed Al Maqbali, Mohammad A A Al-Najjar, Mamoon M D Al-Rshaidat

{"title":"A comprehensive clinical guide for Pneumocystis jirovecii pneumonia: a missing therapeutic target in HIV-uninfected patients.","authors":"Ahmad R Alsayed, Abdullah Al-Dulaimi, Mohammad Alkhatib, Mohammed Al Maqbali, Mohammad A A Al-Najjar, Mamoon M D Al-Rshaidat","doi":"10.1080/17476348.2022.2152332","DOIUrl":"https://doi.org/10.1080/17476348.2022.2152332","url":null,"abstract":"Introduction: Pneumocystis jirovecii is an opportunistic, human-specific fungus that causes Pneumocystis pneumonia (PCP). PCP symptoms are nonspecific. A patient with P. jirovecii and another lung infection faces a diagnostic challenge. It may be difficult to determine which of these agents is responsible for the clinical symptoms, preventing effective treatment. Diagnostic and treatment efforts have been made more difficult by the rising frequency with which coronavirus 2019 (COVID-19) and PCP co-occur.Areas covered: Herein, we provide a comprehensive review of clinical and pharmacological recommendations along with a literature review of PCP in immunocompromised patients focusing on HIV-uninfected patients.Expert opinion: PCP may be masked by identifying co-existing pathogens that are not necessarily responsible for the observed infection. Patients with severe form COVID-19 should be examined for underlying immunodeficiency, and co-infections must be considered as co-infection with P. jirovecii may worsen COVID-19's severity and fatality. PCP should be investigated in patients with PCP risk factors who come with pneumonia and suggestive radiographic symptoms but have not previously received PCP prophylaxis. PCP prophylaxis should be explored in individuals with various conditions that impair the immune system, depending on their PCP risk.","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":"16 11-12","pages":"1167-1190"},"PeriodicalIF":3.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10611592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Exploring predisposing factors and pathogenesis contributing to injuries of donor lungs. 探讨供肺损伤的易感因素及发病机制。

IF 3.9 3区医学

Expert Review of Respiratory Medicine Pub Date : 2022-11-01 DOI: 10.1080/17476348.2022.2157264

Jing Yu, Nan Zhang, Zhiyuan Zhang, Yuping Li, Jiameng Gao, Chang Chen, Zongmei Wen

{"title":"Exploring predisposing factors and pathogenesis contributing to injuries of donor lungs.","authors":"Jing Yu, Nan Zhang, Zhiyuan Zhang, Yuping Li, Jiameng Gao, Chang Chen, Zongmei Wen","doi":"10.1080/17476348.2022.2157264","DOIUrl":"https://doi.org/10.1080/17476348.2022.2157264","url":null,"abstract":"Introduction: Lung transplantation (LTx) remains the only therapeutic strategy for patients with incurable lung diseases. However, its use has been severely limited by the narrow donor pool and potential concerns of inferior quality of donor lungs, which are more susceptible to external influence than other transplant organs. Multiple insults, including various causes of death and a series of perimortem events, may act together on donor lungs and eventually culminate in primary graft dysfunction (PGD) after transplantation as well as other poor short-term outcomes.Areas covered: This review focuses on the predisposing factors contributing to injuries to the donor lungs, specifically focusing on the pathogenesis of these injuries and their impact on post-transplant outcomes. Additionally, various maneuvers to mitigate donor lung injuries have been proposed.Expert opinion: The selection criteria for eligible donors vary and may be poor discriminators of lung injury. Not all transplanted lungs are in ideal condition. With the rapidly increasing waiting list for LTx, the trend of using marginal donors has become more apparent, underscoring the need to gain a deeper understanding of donor lung injuries and discover more donor resources.","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":"16 11-12","pages":"1191-1203"},"PeriodicalIF":3.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10616793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictive factors of nebulized morphine failure in North-African patients with chest trauma: a prospective pilot study. 北非胸外伤患者吗啡雾化失效的预测因素:一项前瞻性试点研究。

IF 3.9 3区医学

Expert Review of Respiratory Medicine Pub Date : 2022-10-01 Epub Date: 2022-10-05 DOI: 10.1080/17476348.2022.2131543

Hela Attia, Helmi Ben Saad, Karim Masmoudi, Imen Bannour, Mouna Ouaz, Kais Gardabbou, Ali Majdoub

{"title":"Predictive factors of nebulized morphine failure in North-African patients with chest trauma: a prospective pilot study.","authors":"Hela Attia, Helmi Ben Saad, Karim Masmoudi, Imen Bannour, Mouna Ouaz, Kais Gardabbou, Ali Majdoub","doi":"10.1080/17476348.2022.2131543","DOIUrl":"https://doi.org/10.1080/17476348.2022.2131543","url":null,"abstract":"Objective: To determine the predictive factors of nebulized morphine (nMOR) failure in patients with chest trauma.Research design and methods: This was an interventional clinical study. Patients admitted with isolated chest trauma with a pain visual analog score > 4 were included. Each patient received 10 mg nMOR. If pain was still > 4 after 10 minutes of nebulization, the latter was repeated every 10 minutes until pain was relieved (i.e. ≤ 4). If pain was > 4 at 30 minutes, nMOR was considered a failure. Patients were divided into two groups: MOR (+) and MOR (-) (good response to and nMOR failure, respectively).Results: Seventy-five patients were included. Analysis of the risk factors revealed that road traffic accidents (relative risk (RR): 0.117 [0.031-0.443]; p = 0.002), number of fractured ribs > 4 (RR: 0.317 [0.092-0.543]; p = 0.006), bilateral injury (RR: 0.114 [0.037-0.349]; p < 0.001), flail chest (RR: 0.120 [0.037-0.386]; p < 0.001), hemothorax (RR: 0.203 [0.062-0.660]; p = 0.008), pulmonary contusion (RR: 0.202 [0.069-0.589]; p = 0.003), and pain at admission > 7 (RR: 0.363 [0.147-0.579]; p = 0.004) were predictors of nMOR failure.Conclusion: Our results can help optimize the analgesic management of chest trauma patients by identifying the most eligible patients to benefit from nMOR.Clinical trial registration: www.clinicaltrials.gov identifier is NCT03580187.","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":"16 10","pages":"1085-1092"},"PeriodicalIF":3.9,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33488406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

DNA repair in lung cancer: a large-scale quantitative analysis for polymorphisms in DNA repairing pathway genes and lung cancer susceptibility. 肺癌DNA修复:DNA修复通路基因多态性与肺癌易感性的大规模定量分析

IF 3.9 3区医学

Expert Review of Respiratory Medicine Pub Date : 2022-09-01 DOI: 10.1080/17476348.2022.2115361

Zexi Liao, Minhan Yi, Jiaxin Li, Yuan Zhang

{"title":"DNA repair in lung cancer: a large-scale quantitative analysis for polymorphisms in DNA repairing pathway genes and lung cancer susceptibility.","authors":"Zexi Liao, Minhan Yi, Jiaxin Li, Yuan Zhang","doi":"10.1080/17476348.2022.2115361","DOIUrl":"https://doi.org/10.1080/17476348.2022.2115361","url":null,"abstract":"Background: The results of associations between single nucleotide polymorphisms (SNPs) of genes in DNA repairing pathway and lung cancer (LC) risk are inconsistent.Methods: We applied allele, dominant and recessive models to explore the risk of researched variants to LC in total LC and subgroups by ethnicity or LC subtypes with a cutoff point of p < 0.05.Results: A total of 76,935 cases and 88,649 controls from 192 articles were included. Among the analyzed 40 variants from 20 genes, we found 9 statistically significant variants in overall populations by allele model, including five SNPs (rs1760944, rs9344, rs13181, rs1001581, and rs915927) increasing LC risk (odd ratios [ORs] = 1.10-1.71) and four SNPs (rs1042522, rs3213245, rs11615, and rs238406) decreasing the risk (ORs = 0.75-0.94). We identified rs1042522 and rs13181 as significant variants for LC in three models. Additionally, we identified differential significant SNPs in ethnic and subtype's analysis with comparison to total population.Conclusions: There are five SNPs in DNA repairing pathway associated with increased LC risk and four others decreased LC risk. Besides, the risky SNPs in different ethnicities and various LC subtypes were partly different, and the contribution of different genotypes to risk alleles were various as well.","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":"16 9","pages":"997-1010"},"PeriodicalIF":3.9,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10447228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The right interface for the right patient in noninvasive ventilation: a systematic review. 无创通气中合适病人的合适接口:一项系统综述。

IF 3.9 3区医学

Expert Review of Respiratory Medicine Pub Date : 2022-08-01 Epub Date: 2022-09-23 DOI: 10.1080/17476348.2022.2121706

Paola Pierucci, Andrea Portacci, Giovanna Elisiana Carpagnano, Paolo Banfi, Claudia Crimi, Giovanni Misseri, Cesare Gregoretti

{"title":"The right interface for the right patient in noninvasive ventilation: a systematic review.","authors":"Paola Pierucci, Andrea Portacci, Giovanna Elisiana Carpagnano, Paolo Banfi, Claudia Crimi, Giovanni Misseri, Cesare Gregoretti","doi":"10.1080/17476348.2022.2121706","DOIUrl":"https://doi.org/10.1080/17476348.2022.2121706","url":null,"abstract":"Introduction: Research in the field of noninvasive ventilation (NIV) has contributed to the development of new NIV interfaces. However, interface tolerance plays a crucial role in determining the beneficial effects of NIV therapy.Areas covered: This systematic review explores the most significant scientific research on NIV interfaces, with a focus on the potential impact that their design might have on treatment adherence and clinical outcomes. The rationale on the choice of the right interface among the wide variety of devices that are currently available is discussed here.Expert opinion: The paradigm 'The right mask for the right patient' seems to be difficult to achieve in real life. Ranging from acute to chronic settings, the gold standard should include the tailoring of NIV interfaces to patients' needs and preferences. However, such customization may be hampered by issues of economic nature. High production costs and the increasing demand represent consistent burdens and have to be considered when dealing with patient-tailored NIV interfaces. New research focusing on developing advanced and tailored NIV masks should be prioritized; indeed, interfaces should be designed according to the specific patient and clinical setting where they need to be used.","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":"16 8","pages":"931-944"},"PeriodicalIF":3.9,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33462492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management Dupilumab诱导的嗜酸性粒细胞增多症：文献综述和临床治疗算法建议

IF 3.9 3区医学

Expert Review of Respiratory Medicine Pub Date : 2022-06-15 DOI: 10.1080/17476348.2022.2090342

M. Caminati, Bianca Olivieri, A. Dama, C. Micheletto, P. Paggiaro, P. Pinter, G. Senna, M. Schiappoli

{"title":"Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management","authors":"M. Caminati, Bianca Olivieri, A. Dama, C. Micheletto, P. Paggiaro, P. Pinter, G. Senna, M. Schiappoli","doi":"10.1080/17476348.2022.2090342","DOIUrl":"https://doi.org/10.1080/17476348.2022.2090342","url":null,"abstract":"ABSTRACT Introduction Dupilumab is a human monoclonal antibody that targets both IL-4 and IL-13 signaling. It is currently indicated for the treatment of asthma, moderate-to-severe atopic dermatitis, and chronic rhinosinusitis with nasal polyps (CRSwNP). Eosinophilia has been reported as a potential adverse event in treated patients. Areas covered A selective search on PubMed and Medline up to January 2022 was performed, by focusing on dupilumab-induced hypereosinophilia described in clinical trials, real-life studies, and case reports. The possible mechanisms underlying dupilumab-induced hypereosinophilia and the eosinophil-related morbidity have also been explored. Expert opinion Dealing with dupilumab-induced hypereosinophilia represents a clinical challenge for clinicians managing patients on dupilumab therapy. An algorithm for the practical management of dupilumab-induced hypereosinophilia has been proposed, in order to properly investigate potential eosinophil-related morbidity and avoid unnecessary drug discontinuation.","PeriodicalId":12103,"journal":{"name":"Expert Review of Respiratory Medicine","volume":"16 1","pages":"713 - 721"},"PeriodicalIF":3.9,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43359794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 23